FGFR3-TACC3 fusions are oncogenic drivers that were first reported in GBMs and bladder urothelial carcinomas (17); in more detail, this unusual fusion was first detected on a series of 97 GBM cases, two of which harbored the FGFR3-TACC3 fusion (18). Here, TACC3 is linked to bladder transitional cell carcinoma.